RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered

RenovoRx, Inc.

Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).
Cash $6.4M as of Dec 31, 2022; expects to fund operations into Q3 2023.
Phase III TIGeR-PaC trial: first interim analysis triggered after 26 events (30% of 86); DMC review underway; results expected within a week.
47 of 114 target patients randomized; second interim analysis expected in 2024.
Operating expenses $10.0M, up from $5.7M; R&D $4.3M, G&A $5.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RenovoRx, Inc. reported year ended December 31, 2022 results: net income Net loss was $9.9 million for the ended December 31, 2022, EPS Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022.

Period: year ended December 31, 2022
Net income: Net loss was $9.9 million for the ended December 31, 2022
EPS: Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022
Result: reported results

Exact text from the filing

● Net loss was $9.9 million for the ended December 31, 2022, compared to net loss of $6.3 million for year ended December 31, 2021. ● Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022, compared to ($1.21) for the year ended December 31, 2021.

View on SEC.gov

Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.